SCHEDULE: Highbridge Capital Discloses 5.2% Stake in OnKure

Highbridge Capital Management, LLC has disclosed a 5.2% beneficial ownership stake in OnKure Therapeutics, Inc.'s Class A Common Stock.

Summary

• Highbridge Capital Management, LLC reported beneficial ownership of 663,607 shares of OnKure Therapeutics, Inc.'s Class A Common Stock.
• This represents a 5.2% stake in the company's Class A Common Stock.
• The ownership percentage is calculated based on 12,823,872 shares of Class A Common Stock outstanding as of May 5, 2025.
• Highbridge Capital Management, LLC acts as an investment adviser to various funds and accounts that directly hold these shares.
• The shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing the control of OnKure Therapeutics, Inc.

Sentiment

Score: 6

Explanation: The filing is a neutral regulatory disclosure of beneficial ownership. However, the disclosure of a significant institutional stake by Highbridge Capital Management, LLC can be interpreted as a moderately positive signal of investor interest in OnKure Therapeutics, Inc.

Positives

• Highbridge Capital Management, LLC, a significant investment firm, has taken a 5.2% beneficial ownership stake in OnKure Therapeutics, Inc., indicating institutional interest.

Future Outlook

NA

Industry Context

Schedule 13G filings are mandatory disclosures by institutional investors who acquire more than 5% beneficial ownership of a company's voting stock, but do not intend to influence or change control of the company. These filings provide transparency into significant institutional holdings and can signal investor confidence or strategic positioning within a sector. For OnKure Therapeutics, Inc., this filing indicates that a notable investment firm, Highbridge Capital Management, LLC, sees value in the company, potentially attracting further investor attention.

Comparison to Industry Standards

• This filing is a standard regulatory disclosure of beneficial ownership.
• The 5.2% stake is a significant institutional position, common among investment firms taking passive stakes in public companies.

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor like Highbridge Capital Management, LLC may increase confidence and potentially attract other investors, potentially influencing stock price positively.
• Company Management: Awareness of a significant passive institutional holder may influence strategic decisions, though Highbridge has stated no intent to influence control.

Key Dates

Keywords

OnKure Therapeutics, Highbridge Capital Management, SEC Filing, Schedule 13G, Beneficial Ownership, Class A Common Stock, Investment Adviser, Institutional Ownership